Wall Street analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will post sales of $37.77 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies’ earnings, with the highest sales estimate coming in at $75.00 million and the lowest estimate coming in at $530,000.00. Dynavax Technologies posted sales of $7.29 million during the same quarter last year, which suggests a positive year over year growth rate of 418.1%. The firm is scheduled to announce its next quarterly earnings report on Monday, March 12th.
According to Zacks, analysts expect that Dynavax Technologies will report full year sales of $37.77 million for the current year, with estimates ranging from $1.31 million to $75.31 million. For the next year, analysts expect that the firm will post sales of $45.40 million per share, with estimates ranging from $39.78 million to $51.01 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same quarter in the prior year, the business earned ($0.90) EPS. The firm’s revenue for the quarter was down 68.8% on a year-over-year basis.
Dynavax Technologies (NASDAQ DVAX) traded up $0.50 on Monday, reaching $18.50. The company had a trading volume of 836,800 shares, compared to its average volume of 898,000. Dynavax Technologies has a twelve month low of $3.70 and a twelve month high of $24.45. The company has a market cap of $1,090.00, a PE ratio of -9.44 and a beta of 1.31.
In other news, insider Robert Coffman sold 7,500 shares of the stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP David Louis Johnson sold 3,092 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares in the company, valued at $144,708. The disclosure for this sale can be found here. 2.90% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vident Investment Advisory LLC grew its holdings in shares of Dynavax Technologies by 3.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after purchasing an additional 4,553 shares in the last quarter. First Republic Investment Management Inc. acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth $2,414,000. Crawford Lake Capital Management LLC acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth $1,481,000. California State Teachers Retirement System grew its holdings in shares of Dynavax Technologies by 12.0% during the 3rd quarter. California State Teachers Retirement System now owns 97,417 shares of the biopharmaceutical company’s stock worth $2,094,000 after purchasing an additional 10,412 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Dynavax Technologies by 29.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 235,310 shares of the biopharmaceutical company’s stock worth $5,060,000 after purchasing an additional 54,149 shares in the last quarter. 70.54% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “$37.77 Million in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/37-77-million-in-sales-expected-for-dynavax-technologies-co-dvax-this-quarter/1818908.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.